- Home
- ORN vs ETON Comparison
ORN vs ETON Comparison
Compare ORN & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORN
- ETON
- Stock Information
- Founded
- ORN 1994
- ETON 2017
- Country
- ORN United States
- ETON United States
- Employees
- ORN N/A
- ETON N/A
- Industry
- ORN Military/Government/Technical
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- ORN Industrials
- ETON Health Care
- Exchange
- ORN Nasdaq
- ETON Nasdaq
- Market Cap
- ORN N/A
- ETON 428.5M
- IPO Year
- ORN 2007
- ETON 2018
- Fundamental
- Price
- ORN $7.72
- ETON $17.33
- Analyst Decision
- ORN Strong Buy
- ETON Strong Buy
- Analyst Count
- ORN 3
- ETON 3
- Target Price
- ORN $12.50
- ETON $27.67
- AVG Volume (30 Days)
- ORN 395.2K
- ETON 221.4K
- Earning Date
- ORN 04-29-2025
- ETON 05-13-2025
- Dividend Yield
- ORN N/A
- ETON N/A
- EPS Growth
- ORN N/A
- ETON N/A
- EPS
- ORN 0.08
- ETON N/A
- Revenue
- ORN $824,375,000.00
- ETON $39,011,000.00
- Revenue This Year
- ORN $3.55
- ETON $92.33
- Revenue Next Year
- ORN $11.66
- ETON $52.62
- P/E Ratio
- ORN $97.47
- ETON N/A
- Revenue Growth
- ORN 15.58
- ETON 23.29
- 52 Week Low
- ORN $4.64
- ETON $3.18
- 52 Week High
- ORN $12.12
- ETON $18.41
- Technical
- Relative Strength Index (RSI)
- ORN 78.32
- ETON 68.29
- Support Level
- ORN $6.30
- ETON $16.43
- Resistance Level
- ORN $7.08
- ETON $17.49
- Average True Range (ATR)
- ORN 0.40
- ETON 0.88
- MACD
- ORN 0.19
- ETON 0.19
- Stochastic Oscillator
- ORN 89.87
- ETON 92.78
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.